Terms: = Kidney tumors AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
59 results:
1. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
[TBL] [Abstract] [Full Text] [Related]
2. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
3. Evolution of cell therapy for renal cell carcinoma.
Wang Y; Suarez ER; Kastrunes G; de Campos NSP; Abbas R; Pivetta RS; Murugan N; Chalbatani GM; D'Andrea V; Marasco WA
Mol Cancer; 2024 Jan; 23(1):8. PubMed ID: 38195534
[TBL] [Abstract] [Full Text] [Related]
4. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract] [Full Text] [Related]
5. HGF-Based car-T Cells Target Hepatocellular carcinoma Cells That Express High Levels of c-Met.
Ma H; Wei W; Liang D; Xu X; Yang D; Wang Q; Wang Y; Wei Q; Sun B; Zhao X
Immunol Invest; 2023 Nov; 52(6):735-748. PubMed ID: 37409941
[TBL] [Abstract] [Full Text] [Related]
6. Systemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line treatment of Metastatic Renal Cell carcinoma.
Korkmaz M; Erylmaz MK
J Coll Physicians Surg Pak; 2023 Jun; 33(6):653-658. PubMed ID: 37300261
[TBL] [Abstract] [Full Text] [Related]
7. Anti-VEGF therapy improves EGFR-vIII-car-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
Dong X; Ren J; Amoozgar Z; Lee S; Datta M; Roberge S; Duquette M; Fukumura D; Jain RK
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898734
[TBL] [Abstract] [Full Text] [Related]
8. Acute kidney Injury in Cancer Immunotherapy Recipients.
Joseph A; Lafarge A; Azoulay E; Zafrani L
Cells; 2022 Dec; 11(24):. PubMed ID: 36552755
[TBL] [Abstract] [Full Text] [Related]
9. Nanobody-based car T cells targeting intracellular tumor antigens.
Li H; Zhong D; Luo H; Shi W; Xie S; Qiang H; Zhu L; Gao L; Liu J; Sun S; Ding Z; Yang X; Lu X
Biomed Pharmacother; 2022 Dec; 156():113919. PubMed ID: 36411612
[TBL] [Abstract] [Full Text] [Related]
10. Is CRP/Albumin Ratio (car) a New Parameter to be Added to Risk Stratification Systems in Metastatic Renal Cell carcinoma Patients?
Uzun M; Yildirim EC; Ekinci F; Semiz HS
J Coll Physicians Surg Pak; 2022 Nov; 32(11):1425-1429. PubMed ID: 36377009
[TBL] [Abstract] [Full Text] [Related]
11. Current and future perspectives on car-T cell therapy for renal cell carcinoma: A comprehensive review.
Kim TJ; Lee YH; Koo KC
Investig Clin Urol; 2022 Sep; 63(5):486-498. PubMed ID: 36067994
[TBL] [Abstract] [Full Text] [Related]
12. Single-cell RNA-Seq reveals the potential risk of anti-mesothelin car T Cell therapy toxicity to different organs in humans.
Wen L; Huang Y; Peng L; Zhao K; Sun Y; Lin Z; Chen Y; Li Z; Qian Q; Tong F; Zhang R; Dong X
Front Immunol; 2022; 13():807915. PubMed ID: 36059490
[TBL] [Abstract] [Full Text] [Related]
13. Next Wave of Targets in the treatment of Advanced Renal Cell carcinoma.
Cardenas LM; Deluce JE; Khan S; Gulam O; Maleki Vareki S; Fernandes R; Lalani AA
Curr Oncol; 2022 Jul; 29(8):5426-5441. PubMed ID: 36005167
[TBL] [Abstract] [Full Text] [Related]
14. Incidence and Risk Factors for Acute kidney Injury After Chimeric Antigen Receptor T-Cell Therapy.
Farooqui N; Sy-Go JPT; Miao J; Mehta R; Vaughan LE; Bennani NN; Wang Y; Bansal R; Hathcock MA; Hayman SR; Johnston PB; Villasboas JC; Paludo J; Ansell SM; Leung N; Lin Y; Herrmann SM
Mayo Clin Proc; 2022 Jul; 97(7):1294-1304. PubMed ID: 35787856
[TBL] [Abstract] [Full Text] [Related]
15. ALK Translocation in ALK-Positive Mesenchymal tumors: Diagnostic and Therapeutic Insights.
Jung M; Moon KC; Bae J; Kim TM; Kim M; Jeon YK; Lee C
Arch Pathol Lab Med; 2022 Dec; 146(12):1460-1470. PubMed ID: 35438749
[TBL] [Abstract] [Full Text] [Related]
16. The tricks for fighting against cancer using car NK cells: A review.
Vahidian F; Khosroshahi LM; Akbarzadeh M; Jahanban-Esfahlan A; Baghbanzadeh A; Ali-Hassanzadeh M; Safarzadeh E
Mol Cell Probes; 2022 Jun; 63():101817. PubMed ID: 35436564
[TBL] [Abstract] [Full Text] [Related]
17. Preclinical Development and Evaluation of Allogeneic car T Cells Targeting CD70 for the treatment of Renal Cell carcinoma.
Panowski SH; Srinivasan S; Tan N; Tacheva-Grigorova SK; Smith B; Mak YSL; Ning H; Villanueva J; Wijewarnasuriya D; Lang S; Melton Z; Ghosh A; Dusseaux M; Galetto R; Heyen JR; Sai T; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Cancer Res; 2022 Jul; 82(14):2610-2624. PubMed ID: 35294525
[TBL] [Abstract] [Full Text] [Related]
18. Single-Cell Analysis of Target Antigens of car-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
Front Immunol; 2021; 12():799206. PubMed ID: 34975912
[TBL] [Abstract] [Full Text] [Related]
19. Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics.
Li W; Wang X; Zhang X; Gong P; Ding D; Wang N; Wang Z
Lipids Health Dis; 2021 Nov; 20(1):160. PubMed ID: 34774030
[TBL] [Abstract] [Full Text] [Related]
20. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.
Kumar AR; Devan AR; Nair B; Vinod BS; Nath LR
Mol Biol Rep; 2021 Dec; 48(12):8075-8095. PubMed ID: 34671902
[TBL] [Abstract] [Full Text] [Related]
[Next]